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Summary
Background: In a phase HI randomized trial, we compared
the effectiveness and tolerability of fadrozole (CGS
16949A), a non-steroidal aromatase inhibitor, to tamoxifen
as first-line endocrine therapy in postmenopausal women
with advanced breast cancer.
Patients and methods: Two hundred twelve eligible pa-
tients were randomized to receive tamoxifen 20 mg daily, or
fadrozole 1 mg twice daily orally until disease progression or
the advent of undue toxicity. The treatments were to be dis-
continued upon disease progression.
Results: Prognostic factors were well balanced between
the treatment groups, except for sites of metastatic disease.
Fadrozole-treated patients had significantly more visceral,
especially liver, involvement and less bone-dominant disease.
Response rates for fadrozole and tamoxifen were similar,
20% and 27% (95% Confidence Limits (CL): 13%-29% and
21%-35%), respectively. Time to treatment failure was
longer in patients randomized to tamoxifen (8.5 months for
tamoxifen vs. 6.1 months for fadrozole), but did not reach
statistical significance after adjustment for prognostic factors
(P — 0.09). Fadrozole, for which a significantly lower per-
centage of clinically relevant toxic effects (WHO toxicity
grade >2) was recorded (27% vs. 13%, respectively; P-
0.009), was better tolerated than tamoxifen. Severe cardio-
vascular events including 3 fatalities were seen only in pa-
tients treated with tamoxifen. Eighty-two patients crossed
over to tamoxifen and 66 patients to fadrozole. Crossover
endocrine therapy led to response or stable disease in 64% of
the patients. The overall survival times of the two treatment
groups were similar.
Conclusions: Fadrozole and tamoxifen showed similar
efficacy as first-line treatments in postmenopausal patients
with advanced breast cancer. Fadrozole was significantly bet-
ter tolerated and may therefore be an appropriate alternative
to tamoxifen, especially for patients predisposed to throm-
boembolic events.
Key words: aromatase inhibitor, breast cancer, CGS
16949A, fadrozole, tamoxifen
Introduction
Breast cancer is the principal site of incidence and
mortality in females in most developed countries. The
incidence in Switzerland ranges from 59.1 in the east-
ern part of the country to 73.5 per 100,000 in the west,
for a total of approximately 3500 new cases per year in
the country as a whole. The standardized mortality rate
for Switzerland is 7.0 per 100,000, or more than 1600
deaths per year, i.e., over 20% of all cancer deaths in
females [1].
Tamoxifen (TAM) is the standard treatment for
postmenopausal patients with hormone-dependent
breast cancer both in the adjuvant setting [2] and in
advanced disease [3]. Although other endocrine ther-
apies such as progestins or aromatase inhibitors dis-
played similar [4, 5] or even higher response rates [6]
and duration of disease control [7], the widespread use
of TAM continued because of its low toxicity.
Estrogens play the most important role in maintain-
ing the growth of established hormone-dependent
breast cancer. Therefore, suppression of circulating
plasma levels of estrogens may induce regression of the
tumour. In postmenopausal women estrogens are main-
ly derived from aromatisation of androgenetic precur-
sors. The most important source is androstenedione of
adrenal glands [8].
The role of the aromatase microsomal cytochrome
P-450-dependent enzyme system is well established as
key in the biosynthesis of estrogens in males and
females [9].
Aromatase is found not only in the ovaries of pre-
menopausal patients but also in the adipose tissue and
muscle, liver, brain, placenta and breast cancer tissue
[10].
Aminoglutethinnde (AG) was originally introduced
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as an anticonvulsant agent an subsequently found to
inhibit steroid genesis. It was first successfully used in a
patient with functional disseminated adrenocortical
carcinoma in 1966 [11] and introduced in the palliative
treatment of advanced breast cancer in 1967 [12].
Fadrozole (CGS 16949A), an imidazol derivate, was
the first second-generation non-steroidal aromatase in-
hibitor to be developed and clinically tested following
the introduction of AG. At a standard dose of 1 mg
b.i.d., with no inhibitory effect on other cytochrome
enzymes of steroid synthesis, the estrogen level was
reduced to 30% of baseline values. Phase I studies
showed fadrozole to be very well tolerated [13,14].
The current study was activated in 1988 to assess
the role of fadrozole as primary endocrine therapy for
metastatic breast cancer as compared to tamoxifen. Pa-
tients with either disease progression or unacceptable
toxicity were given the opportunity to use the alterna-
tive drug, if feasible.
Patients and methods
Eligibility criteria included: histologically and/or cytologically
proven breast cancer, objective evidence of progressive disease,
measurability/evaluability of the disease, ECOG performance sta-
tus < 2, postmenopausal status (>12 months amenorrhea, >52 years
with hysterectomy or biochemical evidence of ovarian function
cessation), indication for hormonal treatment according to the
attending physician, and informed consent. Exclusion criteria were:
previous or concurrent malignant disease, significant renal, cardiac,
hepatic or metabolic dysfunction, any concomitant endocrine dis-
order or treatment, and any prior systemic treatment for breast
cancer except adjuvant therapy completed >12 months before ran-
domization. In November 1992 the exclusion criteria were modified
to allow entry of patients with thyroid hormone medication or with
diabetes mellitus which was under control.
Treatment assignment followed a telephone call to the Coordi-
nating Center where randomization by strata (according to perfor-
mance status (0-1 vs. 2), ER status (positive vs. negative vs. un-
known) and previous hormonal adjuvant treatment (yes vs. no)) took
place. The 'minimization' method was used for treatment assignment
in each stratum [15].
The treatment groups were as follows: arm A, TAM 20 mg/day
p.o. and arm B, fadrozole 1 mg p.o. twice a day. No dose modifica-
tions were prescribed. Concurrent radiation therapy was allowed
except on parameter lesions. Patients were expected to continue the
first treatment until progression or excessive toxicity and investi-
gators were urged to cross to the other drug rather than withdraw
patients from the study. Cross-over dosages for both regimens were
identical to dosages used in the first-line treatment in all cases with
indication for further hormonal treatment. After the second pro-
gression patients were considered to be off study, treated individ-
ually and followed until death.
Fadrozole was supplied to the participating institutions through
the SAKK Coordinating Center by the Ciba-Geigy Pharma, Switzer-
land, and was free of charge.
Therapeutic efficacy and toxicity were assessed according to
WHO criteria [16]. A minimum of 2 months of treatment was re-
quired to consider a case evaluable for response; however, progres-
sive disease could be attributed at any time when clinically suspect-
ed. All cases were reviewed for eligibility, treatment response and
time to treatment failure by two chairpersons (BT and KB).
Study endpoints were defined as follows: time to treatment fail-
ure (TTF), response rate including partial remissions (PR) and com-
plete remissions (CR), toxic events, overall survival (OS) and subjec-
tive benefit (the latter not evaluated in the present report). For the
TTF, measured from randomization date, the following events were
considered as failures: disease progression, excessive toxicity, treat-
ment refusal, addition of other treatments (irradiation, chemother-
apy etc.), crossover and death, whichever occurred first. All types of
failures were recorded. OS was measured from date of random-
ization.
Additional end points were: time to progression (TTP), meas-
ured from randomization date until progression); duration of re-
sponse (DR), measured from randomization date for patients in CR
or PR; 'early failure' rate defined as any failure occurring within the
first 12 weeks of treatment; clinically relevant toxicity (any WHO
toxic event classified as grade > 2).
Statistical analysis
The study was planned to detect a response rate increased from
40% to 60% for patients receiving fadrozole compared with tamo-
xifen. The required sample size was estimated to be 320 patients
(alpha error - 0.05, power - 0.80) and a maximal accrual duration
of 6 years was planned. The study was closed in December 1994
after 6.5 years with 221 patients, yielding a statistical power (0.80)
to detect any 20% difference in response rate. The current analysis
on data updated to December 1995 was performed one year after
the last accrual, including all randomized patients. The median fol-
low-up time of surviving patients was 3 years. The main analysis
focussed upon the main comparison. Since treatment selection after
first failure was not based upon randomization, 'crossover treat-
ments' were not statistically compared.
The chi-square or Fisher's exact tests were used for contingency
tables [17]. The Wilcoxon rank sum test was used for ordered cate-
gorical tables (types of toxicities). Logistic regression was used to
verify which variables predicted response to therapy [18]. TTF, TTP,
DR and OS were estimated according to the Kaplan-Meier product
limit method [19]. The prognostic importance of several variables
with respect to TTF and OS was assessed using both univariate
(log-rank test) and multivariate methods [20].
Dominant disease site was categorized as follows: soft tissue
(breast, primary tumor, lymph nodes and other soft tissues), bone
and viscera. When several sites were involved, viscera were consid-
ered dominant over bone and bone dominant over soft tissue. All
P-values are two sided.
Results
Accrual and patient characteristics
Two hundred twenty-one patients were randomized be-
tween June 1988 and December 1994 by 7 centers of
the SAKK. Three centers (Tessin, St. Gallen and Bern)
contributed 85% of the cases. The remaining 4 centers
(Lausanne, Zurich, Basel and Neuchatel) each contri-
buted < 10% of the cases.
Eligibility and evaluability were reviewed for all
cases. Nine patients (4%, 3 in the TAM and 6 in the
fadrozole arm) were ineligible. The reasons in the TAM
arm were: no metastases and pretreatment with TAM
for advanced disease; in the fadrozole arm: no metas-
tases, lung carcinoma (diagnosed bioptically after treat-
ment failure for lung metastasis), premenopausal status
and altered hepatic function.
One patient in each arm received the other treat-
ment. The characteristics of the 212 eligible patients
are listed in Table 1. Median age at study entry was 65-
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years (range: 40-83 years) in the TAM arm and 65
years (range: 39-87 years) in the fadrozole arm. The
median disease-free interval (calculated from date of
surgery to date of relapse) was 49 months (range:
0-224 months) in the TAM and 43 months (range:
0-230 months) in the fadrozole arm.
Initial sites of disease are listed in Table 2. The dis-
tribution of main localization of metastases is signifi-
cantly different (P = 0.005) between the 2 arms. Fadro-
zole-treated patients had more visceral and less bone
dominant disease. Looking at initial disease sites, the
fadrozole arm has significantly more pleura (P = 0.03)
and liver (P- 0.009) localizations. There was also a
trend for more lung localisations (P= 0.17) and a
higher overall number of involved metastatic sites (P —
0.18).
First treatment: Response and early failure
Three eligible patients (3/212,1%) were not evaluable
for response to first treatment one patient on TAM re-
ceived radiotherapy on parameter bone lesions, added
after 4 weeks, and no data was available on two pa-
tients on fadrozole about follow-up and evaluations.
Patients with early treatment stop (with or without
crossover) due to side effects or physician decision,
were considered as non-responders and included in the
calculation of response rates. Response (and early fail-
ure) according to first treatment were comparable, 27%
and 20% in the TAM and in the fadrozole arms,
respectively (P— 0.26). The approximate 95% confi-
Table 1. Eligible patients characteristics.
TAM
no. (%)
Fadrozole
no. (%)
Total
no. (%)
Performance status
0 55 (51%)
1 39 (36%)
2 13 (12%)
Estrogen receptor status
Negative
55(53%) 110(52%)
36 (34%) 75 (35%)
14 (13%) 27 (13%)
dence limits for CR/PR rate were: 21%-35% for TAM
and 13%-29% for fadrozole. Details can be seen in
Table 3.
Overall, response occurrence was associated with
previous adjuvant hormone therapy {P — 0.05) and
limited number (1-2) of localizations (P - 0.09). Pa-
tients with previous adjuvant hormone therapy experi-
enced more responses (9/21, 43%) than those without
(41/188, 22%). Patients with limited number (1-2) of
localizations had more responses (42/156, 27%) than
those with >3 localizations (8/53,13%).
Patients with soft tissue as dominant disease site
experienced more responses (9/26, 35%) than those
with visceral (27/100, 27%) or bone (13/71, 15%).
Three of the receptor-negative patients (3/26, 12%)
responded to treatment; 41/164 (25%) ER-positive
and 6/19 (32%) ER-unknown responded.
Logistic regression was used to assess treatment
effect after adjustment for other covariates. After ad-
Table Z Initial sites of metastatic disease.
TAM
no. (%)
Fadrozole
no. (%)
Total
no. (%)
Main localization of metastases
Visceral 42 (39%)
Bone 54 (50%)
Soft tissue 11 (10%)
Number of involved metastatic sites
1
2
>3
Initial sites'
Local skin
Distant skin
Local lymphnodes
Distant lymphnodes
Lung
Pleura
Bone
Liver
Brain
Total
50 (47%)
35 (33%)
22 (20%)
15 (14%)
3 (3%)
23 (22%)
24 (22%)
26 (24%)
21 (20%)
72 (67%)
3 (3%)
2 (2%)
107
60 (57%)
30 (29%)
15 (14%)
45 (43%)
27 (26%)
33 (31%)
14 (13%)
5 (5%)
19 (18%)
22 (21%)
35 (33%)
35 (34%)
62 (59%)
13 (12%)
105
102 (48%)
84 (40%)
26 (12%)
95 (45%)
62 (29%)
55 (26%)
29 (14%)
8 (4%)
42 (20%)
46 (22%)
61 (29%)
56 (26%)
134 (63%)
16 (8%)
2 (1%)
212
0-9 fm/mg prot
Positive
>10 fm/mg prot
Unknown
Disease free interval
0-12 months
13-24 months
25-60 months
>60 months
Unknown
Prior endocrine adjuvant t
No
Yes
14
81
12
20
9
30
40
8
(13%)
(76%)
(11%)
(19%)
(8%)
(28%)
(37%)
(7%)
reatment
97
10
Prior adjuvant chemotherapy
No
Yes
Prior radiation therapy
No
Yes
Total
72
35
72
35
107
(91%)
(9%)
(67%)
(33%)
(67%)
(33%)
13
85
7
18
11
27
33
16
93
12
72
33
77
28
105
(12%)
(81%)
(7%)
(17%)
(10%)
(26%)
(31%)
(15%)
(89%)
(11%)
(69%)
(31%)
(73%)
(27%)
27
166
19
38
20
57
73
24
190
22
144
68
149
63
212
(13%)
(78%)
(9%)
(18%)
(9%)
(27%)
(34%)
(11%)
(90%)
(10%)
(68%)
(32%)
(70%)
(30%)
• More than one site can be present in each patient.
Table 3. Response and early failure according to first treatment.
CR/PR
I—IV
PD
r K
p n
rLJ
Farlv toxic death
Early non toxic death
Early stop of treatment
Total
Early failure (occurring
in the first 12 weeks)
TAM
/o/ \
no. (h)
29 (27%)
7
1
LI
SO
1 8
1O
3
0
4
106
26 (25%)
Fadrozole
_ _ /q/\
no. \h)
21 (20%)
J
1 A1 O
9 1
0
1
4
103
34 (33%)
P-value
0.26
0.22
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justment for previous hormonal treatment, number of
localizations, receptor status and dominant disease site
in bone, treatment regimen was not significantly asso-
ciated with response ( P - 0.10). The estimated odds
ratio (OR) for CR/PR for fadrozole vs. TAM was 0.56
(95% CL: 0.28-1.11). Previous hormonal treatment
(OR: 2.9, P= 0.03) and a small number of disease
localizations (OR; 2.6, P- 0.03) were significantly
associated with higher response rate. Dominant disease
site in bone (OR: 0.3, P = 0.04) was significantly asso-
ciated with lower response rate.
Patients not pretreated with adjuvant endocrine
therapy responded slightly better to TAM (P - 0.07) as
well as initial sites in lung (P — 0.15) and in bone (P -
0.15). Patients pretreated with adjuvant endocrine ther-
apy and with main localizations in soft tissue respond-
ed better to fadrozole but the number of patients in
both groups is small (see Table 4).
First treatment: Time to failure, duration of response and
survival
The estimated median TTF is longer in the TAM
group, 8.5 months versus 6.1 months in the fadrozole
group (log-rank P- 0.05) (Figure 1). The one-year
failure- free survival was 36 + 5% and 27 + 4%. The
most frequent cause of failure was disease progression.
Other causes were: cross-over (7 TAM, 5 fadrozole),
addition of other treatments such as irradiation or sur-
gery (4 TAM, 1 fadrozole), early stop (1 fadrozole),
refusal (1 TAM) and death (4 TAM, 2 fadrozole).
Cox regression analysis was used to assess the treat-
ment effect on TTF after adjustment for other co-
variates. TTF was not significantly associated with ini-
tial treatment after adjustment for performance status,
disease-free interval, number of localizations, receptor
Table 4. Response by ER status, pretreatment and metastatic site.
Estrogen receptor status
Negative
0-9 fm/mg prot
Positive
>10 fm/mg prot
Unknown
Prior endocrine adjuvant
No
Yes
TAM
N
14
80
12
CR/
PR
1
24
4
treatment
96
10
Prior adjuvant chemotherapy
No
Yes
71
35
Main localization of metastases
Visceral
Bone
Soft tissue
42
53
11
Number of involved metastatic
26
3
21
8
15
11
3
sites
%
(7%)
(30%)
(33%)
(27%)
(30%)
(30%)
(23%)
(36%)
(21%)
(27%)
Fadrozole
N
12
84
7
92
11
70
33
58
30
15
CR/
PR
2
17
2
15
6
16
5
12
3
6
%
(17%)
(20%)
(29%)
(16%)
(55%)
(23%)
(15%)
(21%)
(10%)
(40%)
1
2
Initial sites*
Local skin
Distant skin
Local lymphnodes
Distant lymphnodes
Lung
Pleura
Bone
Liver
Brain
Total
49
35
22
15
11
3
15
3
23
24
26
21
71 15
3 2
2 0
106 29
(31%)
(31%)
(14%)
(33%)
(26%)
(29%)
(35%)
(29%)
(21%)
(67%)
45 11
27 5
31 5
14
5
18
22
33
34
60
13
0
103 21
(24%)
(19%)
(16%)
(36%)
(20%)
(28%)
(23%)
(18%)
(24%)
(12%)
(15%)
* More than one site can be present in each patient
Time to Failure
Figure I. Time to failure (TTF) for pa-
tients 105 patients who received fadro-
zole and 107 patients who received
tamoxifen.
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status, or presence of bone or liver lesions. The hazard
ratio for fadrozole was 1.30 compared to TAM as ref-
erence (95% CL: 0.96-1.75, P = 0.09).
An additional evaluation of time to progression
(TTP) was performed. In TTP calculations, patients
failing without progression (early crossover or treat-
ment stop, refusal, death, etc.) are 'censored' at the time
of occurrence and not considered as failures. Because
of the difference in censoring mechanism, TTP is sig-
nificantly longer in the TAM group (log-rank P — 0.01).
The median response duration is 19.8 months in the
TAM group and 15 months in the fadrozole group
(log-rank P = 0.35) (Figure 2).
OS is similar in the two arms (log-rank P= 0.90)
(Figure 3). Cox regression showed that neither initial
treatment adjusted for performance status, dominant
disease site in soft tissue, number of localizations,
receptor status, presence of bone and liver lesions,
were significantly associated with OS. The hazard ratio
for fadrozole is 0.91 compared to TAM as reference
(95% CL: 0.63-1.32, P- 0.63). OS with more than
25% of patients alive at 5 years is unexpectedly high in
our study population with a substantial proportion of
unfavourable patient characteristics.
First treatment: Side effects
Two hundred eleven eligible patients were considered
assessable for toxic effects of the first treatment. One
patient refused follow-up and examinations. Details
with worst toxicity per patient attributed to the ran-
domised treatment are presented in Table 5. There was
significantly more clinically relevant toxicity (any
WHO >2) in patients randomized to TAM. Cardiovas-
cular events, including three fatalities, were observed
only in patients treated with TAM. One patient died of
Table 5. First treatment: patients worst toxicity (WHO grade).'
Thromboembolic
2
Death while on
Hot flushes
1
2
3
4
Insomnia
1
2
Nausea/vomiting
1
2
Skin
1
Other
Yes
Any toxic effect
Yes
Clinical relevant 1
Yes
Total patients
TAM
no. (%)
disease
1(1%)
treatment 3 (3%)
9 (8%)
11(10%)
4 (4%)
2 (2%)
1(1%)
3 (3%)
1(1%)
0
0
12(11%)
37 (35%)
toxicity (any WHO > 2)
29 (27%)
107
Fadrozole
no. (%)
0
0
14 (13%)
9(9%)
2 (2%)
0
2 (2%)
0
3 (3%)
1 (1%)
1 (1%)
6 (5%)
31 (30%)
13 (13%)
104
P-value
0 12\J. 1 £•
0 IfiV. / vt
0.42
0.16
0.49
0.22
0.47
0.009
• Toxicities - 0 are not reported.
autoptically confirmed bilateral pulmonary embolism 9
days after starting the treatment with TAM (early toxic
death). Another patient with no known pre-existing
cardiopathy died of a cardiovascular event 5 weeks
after onset of treatment with TAM. A pulmonary
embolism as possible cause of death was suspected, but
no autopsy was performed. A further patient died at
home of a cardiovascular event 10 days after treatment
onset with TAM. A TAM effect was suspected but not
o.o
Response Duration
Years
Figure 2. Duration of response for pa-
tients 105 patients who received fadro-
zole and 107 patients who received
tamoxifen.
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Overall Survival
Years
Figure 3. Overall survival for patients
105 patients who received fadrozole
and 107 patients who received tamo-
xifen.
proven by autopsy. Additional TAM side effects were:
depression, headache, increased bone pain, inappet-
ence, gastric pain, fatigue, vaginal flora, hypercalcemia
and hyperuricemia (with acute renal failure); for fadro-
zole: fatigue, flare in bone scan, inappetence, weakness
and somnolence.
Nine patients (8 TAM and 1 fadrozole) discontinued
the first treatment because of side effects; for TAM:
thromboembolic disease in three cases, hypercalcemia,
increased bone pain, hot flushes, headache and ma-
laise, gastric pain with inappetence and nausea, and for
fadrozole: weakness and dizziness in one case each.
Second treatment (cross-over) efficacy
One hundred ninety-five patients stopped (93%) the
first treatment (96 after tamoxifen, 99 after fadrozole).
One hundred forty-eight patients (76%) crossed over to
TAM or fadrozole (82 to TAM and 66 to fadrozole).
The rate of crossover to fadrozole was significantly
lower than the one to TAM (P - 0.006). Since treat-
ment selection after first failure is not random, further
statistical comparisons of TAM and fadrozole as sec-
ond treatment are biased and have therefore not been
performed.
Response and early failure according to cross-over
treatment are summarized in Table 6. For 2 patients on
fadrozole it was too early to assess response. Twenty-
four of 82 patients (29%) who crossed to TAM and 6
of 64 patients (9%) who crossed to fadrozole had an
objective response. Thirty-four patients treated with
TAM and 29 patients treated with fadrozole as cross-
over treatment achieved stabilisation of their disease
after having failed first-line endocrine therapy for ad-
vanced breast cancer. The median duration of cross-
over treatment was 254 days for TAM and 112 days for
fadrozole. The median duration of CR, PR and stable
disease was 12 months for TAM and 10 months for
fadrozole.
Response to cross-over treatment by initial response
is shown in Tables 9 and 10.
Second treatment (cross-over) toxicity
One hundred forty-eight patients were considered
assessable for the toxicity of their crossover treatment.
Patterns and grades of toxicites with TAM and fadro-
zole as randomised treatments were similar. Toxicity >
WHO grade 2 was more frequently observed in pa-
tients crossed to TAM (23%) than in those crossed to
fadrozole (17%). An additional thromboembolic event,
but no further fatalities, was observed among the
TAM-treated patients. Five patients (2 on TAM and 3
on fadrozole) stopped the second treatment because of
toxicity. The reasons for discontinuation of TAM were
hypercalcemia, and severe dyspnea 2-4-hours after
Table 6. Response and early failure according to cross over treat-
ment.
CR/PR
CR
PR
NC
PD
ENTD
Early stop of treatment
Total
Early failure (occurring in the
first 12 weeks)
TAM
no. (%)
24 (29%)
7
17
34
17
1
6
82
23 (28%)
Fadrozole
no. (%)
6(9%)
2
4
29
17
2
10
64
29 (45%)
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ingestion of tamoxifen with a positive rechallenge test
after 2 weeks; for fadrozole they were conjunctivitis
and headache, headache and malaise, and skin reaction
in the form of acute angioedema of the face and neck
without visceral involvement.
One patient received fadrozole for 9 months and
TAM for 18 months before diagnosis of a second tu-
mor (ovarian cancer).
A total of 189 patients were exposed to TAM and
170 to fadrozole and all were considered assessable for
'overall toxicity' defined as the sum of all toxicities ob-
served during randomized and cross-over treatments.
Twenty-five percent of all TAM-exposed patients, but
only 14% of all fadrozole-exposed patients, experi-
enced clinically relevant side effects. The 95% CL
were: 19%-31% for TAM and 9%-19% for fadrozole.
Discussion
The choice of the agent to be used in postmenopausal
patients with advanced breast cancer and the indication
for hormonal treatment is mainly based on the agent's
toxicity profile. TAM remained the standard treatment
despite the fact that several studies have shown consid-
erably higher response rates for medroxyprogesterone
acetate MPA [6] or AG [7] when used as first-line treat-
ment and compared in randomized studies to TAM.
However, the higher response rate did not translate
into a longer time to treatment failure, and toxicity was
usually greater with AG 1000 mg daily plus gluco-
corticoid replacement therapy or MPA 1000 mg
daily.Two previously published studies also compared
TAM to AG. Response rate, response duration and
time to treatment failure were similar in TAM- and
AG-treated patients [5,25].
Another study compared the new selective non-
reversible steroidal aromatase inhibitor formestane
with TAM as first-line treatment in postmenopausal
women with advanced breast cancer. Of the 348 pa-
tients evaluable for response, 33% had objective
responses to formestane and 37% to TAM. Time to
progression and time to treatment failure were signifi-
cantly longer in TAM-treated patients [26].
Our study was closed in December 1994 after 6.5
years of accrual. The trend of the response rate in
favour of TAM, seen in a previous interim report, was
confirmed in the current evaluation, but did not attain
statistical significance [21].
The difference in TTF between the treatment arms
is borderline-significant.
Patient characteristics were well balanced between
the treatment arms with respect to performance status,
estrogen receptor status and disease-free interval from
diagnosis to first relapse, and prior adjuvant hormonal
and chemo-therapy. However, there was a statistically
significant difference between the treatment arms with
regard to predominant localisation of disease at study
entry. The fadrozole-treated patients had significantly
more pleura (P - 0.03) and liver (P - 0.009) localisa-
tions. There was also a trend toward more lung involve-
ment, resulting in more unfavourable visceral and less
bone-dominant disease site for patients randomised to
fadrozole.
This disparity in patient characteristics has probably
caused the slightly lower response rate (which, how-
ever, did not reach statistical significance) of patients
randomized to fadrozole. We assume that the border-
line-significantly shorter TTF of patients randomized
to fadrozole is due to the imbalance as well. The ob-
served difference in TTF might also be due to physician
reluctance to use a new drug (fadrozole) as first-line
treatment when a widely accepted, well known and
usually well tolerated standard treatment is available.
Our hypothesis is supported by the fact that more pa-
tients receiving fadrozole were crossed to TAM than
vice versa (P= 0.006). A double blind trial design
could have averted this source of bias. In an attempt to
correct for the imbalance, Cox regression analysis was
used to asses the treatment effect on TTF after adjust-
ment for other covariates. The non-statistically-signifi-
cant hazard ratio for patients treated with fadrozole
was 1.30 compared to the ratio for TAM-treated pa-
tients (P - 0.09). Thus far this imbalance has not affect-
ed overall survival which was similar in the two arms.
Interestingly, the TTF for patients with lung metastases
and bone metastases were identical. Patients with vis-
ceral-predominant disease had an almost identical TTF
to that of patients with bone-predominant disease.
Responses to crossover treatments have been ob-
served in both directions, but conclusions might be
biased due to the lack of randomized assignment and
to the fact that fewer patients received fadrozole as
second-line treatment. Overall, early failure was seen in
36% of the patients after crossover, showing that the
majority of patients did benefit from the second hor-
monal treatment for considerable periods of time (me-
dian duration of CR, PR and stable disease between 10
and 12 months). One of 9 patients with initial progres-
sion on tamoxifen had a partial remission on fadrozole
and an additional 3 of the 9 had disease stabilization as
best response to fadrozole. One of 16 patients with ini-
tial progression on fadrozole responded to tamoxifen
and another 6 of these had disease stabilization when
treated with fadrozole. It appears that about half of the
patients with straightforward disease progression on
first-line hormonal treatment might have experienced a
palliative effect when they were exposed to a second
endocrine treatment. Although there were few objec-
tive responses, the long median duration of CR, PR
and stable disease shows that many patients probably
derived a beneficial effect from disease stabilization.
The two treatments had only a few toxic effects, with
hot flushes, as expected, being the most frequently tox-
icity observed. Skin reactions, seen in up to 15% of
patients treated with the previously-used non-steroidal
aromatase inihibitor AG, were present in only 3 of 170
patients exposed to fadrozole. The reasons for cessa-
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tion of treatment may reflect not only objective toxicity
but also the treatment-associated subjective experience
of the patients. Physicians participating in this study
appeared reluctant to continue using fadrozole. This
fact, as mentioned above, could have contributed not
only to the shorter time to treatment failure in patients
randomized to fadrozole but also to a closer observa-
tion of patients with regard to expected (skin reactions)
and unexpected toxic effects. Cardiovascular incidents
have been observed only in the TAM- treated group.
Thromboembolic events, including 3 treatment-associ-
ated deaths, were seen in 4 patients randomized to
TAM. A further instance of pulmonary embolism was
observed in 82 patients receiving TAM as crossover
treatment. Significantly more patients randomised to
TAM (27%) had clinically relevant toxicity than pa-
tients randomized to fadrozole (13%).
The results obtained in our study with regard to
response rate and time to treatment failure are some-
what inferior to the ones expected when the study was
planned, and as compared to the literature. In patients
with recurrent or metastatic breast cancer, TAM is the
most frequently chosen agent for initial endocrine ther-
apy with an expected overall complete and partial re-
sponse rate of 30%-40% [3,22].
However, in recently published multicenter trials
using TAM 20 mg daily orally in a randomized com-
parison to MPA or AG as initial endocrine therapy for
patients with metastatic breast cancer, response rates
for TAM were considerably lower than expected - 17%
and 27%, respectively [6, 7]. The time to treatment
failure for TAM-treated patients was brief in both stud-
ies: 5.5 months and 3.5 months, respectively. Response
rate and median time to treatment failure in our multi-
center trial were comparable to the ones in these
recently published trials. The lower response rate and
shorter TTF are probably due to the inclusion of pa-
tients with more unfavorable prognosis and to the
strict application of response criteria (e.g., evaluation
by two chair persons, inclusion of all patients in the
analysis, etc.). In recently reported phase II studies of
fadrozole in pretreated postmenopausal patients with
advanced breast cancer, relatively low response rates of
23% (95% CL: 12%-34%) in a single-institution study
and of 16% (95% CL: 12%-20%) in a large multi-
center study with external peer review were observed,
with a TTF of approximately 4 months in both studies
[23, 24]. The median overall survival in our study was
higher than in both of the above-cited studies despite
the fact that our study population included a consider-
able number of patients with visceral tumour lesions as
predominate site of disease and involvement of multi-
ple organ sites. Other factors of patient selection and
treatment modalities after failure of study treatment
may have contributed to these favorable results.
Conclusion
Fadrozole is a new non-steroidal aromatase inhibitor
without need of glucocorticoid replacement and with
little toxicity. In our experience both drugs were simi-
larly effective, and fadrozole was associated with sig-
nificantly less clinically-relevant toxicity. It may be
considered as an alternative to TAM, especially for
patients with a predisposition to thromboembolic
events.
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